Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy

Analysts at Goldman Sachs upgraded Vertex Pharmaceuticals

from Neutral to Buy. The target price for Vertex Pharmaceuticals has been raised from $109 to $131. Vertex Pharma shares have gained 16.00% over the past 52 weeks, while the S&P 500 index has surged 20.10% in the same period. Vertex Pharmaceuticals' shares rose 0.22% to $95.25 in pre-market trading.